References
1.Flemmer MC, et al. Blood B-type natriuretic peptide levels and dialysis: Present assessment and future analyses. South Med J 2008;101:1094–1100.
2.Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635–641.
3.Gould PA, D’Agostino J, Schneider HG, et al. Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure. Eur J Heart Fail 2006;8:263–269.
4.O’Neill JO, Bott-Silverman CE, McRae AT III, et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 2005;149:363–369.
5.Zoccali C, Mallamaci F, Benedetto FA, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508–1515.
6.Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005;46:610–620.
7.Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003;108:560–565.
8.Goetze JP, Jensen G, Moller S, et al. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest 2006;36:8–15.
9.McCullough PA, Duc P, Omland T, et al; Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571–579.
10.Maeder MT, Mueller C, Pfisterer ME, et al. Use of B-type natriuretic peptide outside of the emergency department. Int J Cardiol 2008;127:5–16.
11.Sheen V, Bhalla V, Tulua-Tata A, et al. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 2007;153:244. e1–e5.
12.Wahl HG, Graf S, Renz H, et al. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004;50:1071–1074.
13.Maeder M, Wolber T, Rickli H, et al. B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure. Int J Cardiol 2007;120:391–398.
14.Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912–1918.
15.Zilch O, Vos PF, Oey PL, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007;25:1285–1289.
16.Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69:2268–2273.
17.Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392–2397.